 Check-Cap Ltd. the Company or Check-Cap NASDAQ: CHEK, a clinical-stage medical diagnostics company advancing the development of C-Scan, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that the Company received a letter from the Nasdaq Listing Qualifications the Letter, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550a2, which requires listed securities to maintain a minimum bid price of 1.00 per share. 